Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 293 | 2024 | 2970 | 22.860 |
Why?
|
Genes, BRCA1 | 86 | 2023 | 192 | 10.260 |
Why?
|
Genes, BRCA2 | 72 | 2023 | 161 | 8.550 |
Why?
|
Genetic Predisposition to Disease | 140 | 2023 | 2316 | 8.200 |
Why?
|
BRCA1 Protein | 61 | 2023 | 201 | 8.180 |
Why?
|
BRCA2 Protein | 52 | 2023 | 159 | 7.000 |
Why?
|
Genetic Testing | 52 | 2023 | 534 | 5.740 |
Why?
|
Ovarian Neoplasms | 56 | 2023 | 756 | 5.230 |
Why?
|
Mutation | 114 | 2023 | 4078 | 5.210 |
Why?
|
Triple Negative Breast Neoplasms | 15 | 2023 | 147 | 5.140 |
Why?
|
Germ-Line Mutation | 42 | 2022 | 339 | 4.560 |
Why?
|
Nigeria | 41 | 2024 | 155 | 3.860 |
Why?
|
Female | 375 | 2024 | 45399 | 3.860 |
Why?
|
Humans | 458 | 2024 | 87949 | 3.120 |
Why?
|
Polymorphism, Single Nucleotide | 73 | 2023 | 2395 | 2.930 |
Why?
|
Neoplasms | 36 | 2023 | 2984 | 2.870 |
Why?
|
Middle Aged | 207 | 2024 | 25477 | 2.730 |
Why?
|
Biomarkers, Tumor | 30 | 2021 | 1511 | 2.560 |
Why?
|
Genomics | 10 | 2020 | 740 | 2.470 |
Why?
|
Heterozygote | 50 | 2020 | 369 | 2.410 |
Why?
|
Adult | 192 | 2024 | 26131 | 2.330 |
Why?
|
Genetic Counseling | 18 | 2023 | 101 | 2.180 |
Why?
|
Genome-Wide Association Study | 39 | 2023 | 1659 | 2.110 |
Why?
|
Receptors, Estrogen | 27 | 2022 | 385 | 2.070 |
Why?
|
Receptors, Progesterone | 16 | 2018 | 167 | 2.030 |
Why?
|
Carcinoma, Ductal, Breast | 10 | 2021 | 157 | 1.950 |
Why?
|
Receptor, ErbB-2 | 21 | 2023 | 236 | 1.850 |
Why?
|
Chromosomes, Human, Pair 9 | 21 | 2016 | 86 | 1.850 |
Why?
|
Health Status Disparities | 6 | 2023 | 175 | 1.810 |
Why?
|
Aged | 124 | 2024 | 18750 | 1.640 |
Why?
|
Risk Factors | 83 | 2024 | 5405 | 1.620 |
Why?
|
Gene Expression Regulation, Neoplastic | 26 | 2021 | 1239 | 1.600 |
Why?
|
Ovariectomy | 18 | 2022 | 81 | 1.550 |
Why?
|
Case-Control Studies | 55 | 2024 | 1843 | 1.530 |
Why?
|
Glucuronosyltransferase | 9 | 2014 | 185 | 1.490 |
Why?
|
Risk Assessment | 39 | 2021 | 2274 | 1.460 |
Why?
|
Alleles | 29 | 2021 | 1129 | 1.440 |
Why?
|
DNA Methylation | 12 | 2018 | 650 | 1.430 |
Why?
|
Estrogen Receptor alpha | 10 | 2017 | 147 | 1.380 |
Why?
|
Breast | 19 | 2023 | 290 | 1.360 |
Why?
|
Precision Medicine | 6 | 2023 | 407 | 1.290 |
Why?
|
Promoter Regions, Genetic | 16 | 2019 | 951 | 1.280 |
Why?
|
Neoadjuvant Therapy | 10 | 2023 | 354 | 1.280 |
Why?
|
Breast Neoplasms, Male | 9 | 2019 | 31 | 1.270 |
Why?
|
Mammography | 15 | 2018 | 465 | 1.260 |
Why?
|
Early Detection of Cancer | 8 | 2019 | 408 | 1.250 |
Why?
|
Colorectal Neoplasms | 11 | 2019 | 956 | 1.240 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2017 | 520 | 1.210 |
Why?
|
Prognosis | 45 | 2023 | 3729 | 1.200 |
Why?
|
Health Services Accessibility | 7 | 2021 | 411 | 1.200 |
Why?
|
Neoplasm Staging | 26 | 2023 | 1967 | 1.140 |
Why?
|
Genotype | 36 | 2023 | 1866 | 1.140 |
Why?
|
Tumor Suppressor Proteins | 9 | 2020 | 287 | 1.130 |
Why?
|
Tamoxifen | 7 | 2023 | 168 | 1.100 |
Why?
|
Body Height | 5 | 2021 | 100 | 1.090 |
Why?
|
Magnetic Resonance Imaging | 13 | 2020 | 3425 | 1.090 |
Why?
|
Neoplasms, Second Primary | 11 | 2014 | 258 | 1.080 |
Why?
|
Mass Screening | 7 | 2018 | 627 | 1.060 |
Why?
|
Up-Regulation | 4 | 2018 | 726 | 1.060 |
Why?
|
Proto-Oncogene Proteins c-myc | 6 | 2015 | 126 | 1.050 |
Why?
|
Gene Expression Profiling | 17 | 2021 | 1414 | 1.040 |
Why?
|
Chromosome Deletion | 13 | 2001 | 229 | 1.040 |
Why?
|
Chromosome Aberrations | 9 | 2014 | 389 | 1.030 |
Why?
|
Aged, 80 and over | 47 | 2023 | 6655 | 1.010 |
Why?
|
Neoplasm Proteins | 10 | 2019 | 539 | 1.000 |
Why?
|
Paclitaxel | 8 | 2019 | 476 | 0.960 |
Why?
|
Mastectomy | 13 | 2023 | 243 | 0.960 |
Why?
|
Jews | 6 | 2018 | 42 | 0.950 |
Why?
|
DNA Mutational Analysis | 18 | 2021 | 531 | 0.950 |
Why?
|
Genetic Services | 3 | 2023 | 7 | 0.930 |
Why?
|
United States | 32 | 2023 | 6809 | 0.930 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 3 | 2022 | 114 | 0.930 |
Why?
|
Cell Line, Tumor | 25 | 2021 | 2513 | 0.900 |
Why?
|
Medical Oncology | 7 | 2021 | 374 | 0.880 |
Why?
|
Cohort Studies | 31 | 2023 | 2802 | 0.870 |
Why?
|
Ubiquitin-Protein Ligases | 6 | 2020 | 170 | 0.860 |
Why?
|
Parity | 5 | 2015 | 94 | 0.860 |
Why?
|
Breast Feeding | 3 | 2020 | 98 | 0.860 |
Why?
|
Neoplasms, Basal Cell | 3 | 2018 | 9 | 0.850 |
Why?
|
Founder Effect | 6 | 2018 | 104 | 0.850 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2020 | 2516 | 0.840 |
Why?
|
Fallopian Tube Neoplasms | 3 | 2019 | 36 | 0.840 |
Why?
|
Pancreatic Neoplasms | 6 | 2019 | 656 | 0.830 |
Why?
|
Tumor Suppressor Protein p53 | 7 | 2022 | 404 | 0.830 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2023 | 1347 | 0.830 |
Why?
|
Epigenesis, Genetic | 8 | 2018 | 495 | 0.820 |
Why?
|
Capacity Building | 4 | 2020 | 11 | 0.820 |
Why?
|
Clonal Evolution | 1 | 2021 | 15 | 0.810 |
Why?
|
Genetic Loci | 12 | 2019 | 252 | 0.810 |
Why?
|
Exons | 8 | 2016 | 452 | 0.800 |
Why?
|
Body Mass Index | 9 | 2021 | 765 | 0.790 |
Why?
|
Gene Deletion | 10 | 2002 | 341 | 0.760 |
Why?
|
Germ Cells | 4 | 2023 | 130 | 0.760 |
Why?
|
RNA, Long Noncoding | 2 | 2021 | 112 | 0.760 |
Why?
|
Healthcare Disparities | 7 | 2023 | 390 | 0.760 |
Why?
|
Cross-Sectional Studies | 9 | 2023 | 1682 | 0.760 |
Why?
|
Risk | 25 | 2022 | 660 | 0.750 |
Why?
|
Drug Resistance, Neoplasm | 8 | 2019 | 610 | 0.740 |
Why?
|
Demography | 2 | 2023 | 179 | 0.740 |
Why?
|
Genomic Instability | 5 | 2021 | 79 | 0.740 |
Why?
|
Preventive Health Services | 2 | 2019 | 39 | 0.730 |
Why?
|
Introns | 5 | 2021 | 296 | 0.730 |
Why?
|
Medicine, African Traditional | 1 | 2020 | 3 | 0.730 |
Why?
|
Radiation Oncology | 2 | 2020 | 121 | 0.730 |
Why?
|
Health Personnel | 2 | 2022 | 207 | 0.730 |
Why?
|
Male | 73 | 2023 | 41697 | 0.730 |
Why?
|
Alternative Splicing | 5 | 2016 | 207 | 0.720 |
Why?
|
Peritoneal Neoplasms | 3 | 2019 | 181 | 0.720 |
Why?
|
Biomedical Research | 5 | 2019 | 385 | 0.720 |
Why?
|
Doxorubicin | 9 | 2020 | 297 | 0.720 |
Why?
|
In Situ Hybridization, Fluorescence | 17 | 2022 | 353 | 0.720 |
Why?
|
Pedigree | 18 | 2018 | 968 | 0.710 |
Why?
|
Pharmacogenetics | 2 | 2021 | 441 | 0.700 |
Why?
|
Antineoplastic Agents | 8 | 2018 | 2392 | 0.690 |
Why?
|
Antimetabolites, Antineoplastic | 5 | 2020 | 237 | 0.690 |
Why?
|
Genes, erbB-2 | 4 | 2009 | 25 | 0.680 |
Why?
|
Bromobenzenes | 1 | 2019 | 2 | 0.680 |
Why?
|
Copper-transporting ATPases | 1 | 2019 | 12 | 0.680 |
Why?
|
CpG Islands | 5 | 2016 | 158 | 0.680 |
Why?
|
Molybdenum | 1 | 2019 | 12 | 0.680 |
Why?
|
Benzothiazoles | 1 | 2019 | 17 | 0.670 |
Why?
|
Checkpoint Kinase 2 | 2 | 2018 | 24 | 0.670 |
Why?
|
Young Adult | 30 | 2024 | 6151 | 0.670 |
Why?
|
Neovascularization, Pathologic | 3 | 2019 | 364 | 0.670 |
Why?
|
DNA-Binding Proteins | 13 | 2016 | 1224 | 0.670 |
Why?
|
Clinical Trials as Topic | 6 | 2020 | 1141 | 0.670 |
Why?
|
Fluorobenzenes | 1 | 2019 | 33 | 0.660 |
Why?
|
Transcription Factors | 12 | 2017 | 1622 | 0.660 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 2 | 2018 | 53 | 0.660 |
Why?
|
Minority Groups | 5 | 2018 | 140 | 0.660 |
Why?
|
Tumor Microenvironment | 4 | 2021 | 447 | 0.660 |
Why?
|
Haplotypes | 15 | 2019 | 637 | 0.660 |
Why?
|
beta Catenin | 4 | 2015 | 263 | 0.660 |
Why?
|
Proportional Hazards Models | 21 | 2021 | 856 | 0.650 |
Why?
|
Molecular Chaperones | 1 | 2019 | 112 | 0.640 |
Why?
|
Physicians | 4 | 2022 | 683 | 0.640 |
Why?
|
Genetic Variation | 14 | 2021 | 1366 | 0.630 |
Why?
|
Polymorphism, Genetic | 9 | 2012 | 825 | 0.630 |
Why?
|
Women, Working | 1 | 2017 | 7 | 0.620 |
Why?
|
Carcinoma | 3 | 2014 | 441 | 0.620 |
Why?
|
Premenopause | 6 | 2013 | 54 | 0.600 |
Why?
|
Medicaid | 1 | 2020 | 225 | 0.600 |
Why?
|
Genome, Human | 6 | 2020 | 766 | 0.600 |
Why?
|
Brain Neoplasms | 5 | 2016 | 773 | 0.590 |
Why?
|
Hereditary Breast and Ovarian Cancer Syndrome | 2 | 2018 | 10 | 0.590 |
Why?
|
Molecular Epidemiology | 2 | 2019 | 53 | 0.590 |
Why?
|
Circulating MicroRNA | 1 | 2016 | 12 | 0.560 |
Why?
|
Antineoplastic Agents, Hormonal | 4 | 2017 | 156 | 0.560 |
Why?
|
Odds Ratio | 21 | 2022 | 682 | 0.550 |
Why?
|
Bibliometrics | 1 | 2016 | 37 | 0.540 |
Why?
|
Fanconi Anemia Complementation Group F Protein | 3 | 2019 | 6 | 0.540 |
Why?
|
Biological Products | 1 | 2018 | 146 | 0.540 |
Why?
|
Chromosome Mapping | 19 | 2019 | 1077 | 0.540 |
Why?
|
Socioeconomic Factors | 7 | 2020 | 572 | 0.540 |
Why?
|
Disease-Free Survival | 12 | 2023 | 1210 | 0.540 |
Why?
|
Genetic Association Studies | 12 | 2019 | 294 | 0.540 |
Why?
|
Microsatellite Repeats | 4 | 2016 | 148 | 0.530 |
Why?
|
Survival Analysis | 19 | 2021 | 1539 | 0.530 |
Why?
|
Body Weight | 3 | 2021 | 451 | 0.530 |
Why?
|
Purine-Nucleoside Phosphorylase | 11 | 2001 | 23 | 0.530 |
Why?
|
Adenocarcinoma | 6 | 2011 | 1182 | 0.530 |
Why?
|
Estrogen Receptor beta | 2 | 2012 | 25 | 0.520 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 10 | 2018 | 108 | 0.520 |
Why?
|
Uganda | 5 | 2024 | 36 | 0.520 |
Why?
|
Neoplasms, Glandular and Epithelial | 4 | 2017 | 75 | 0.510 |
Why?
|
Retrospective Studies | 28 | 2023 | 8780 | 0.510 |
Why?
|
Genes, Tumor Suppressor | 13 | 2016 | 159 | 0.500 |
Why?
|
Genetic Carrier Screening | 8 | 2016 | 60 | 0.500 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 78 | 0.500 |
Why?
|
Chromosomes, Human, Pair 5 | 4 | 2008 | 109 | 0.500 |
Why?
|
Transcriptome | 5 | 2023 | 613 | 0.490 |
Why?
|
MicroRNAs | 6 | 2019 | 545 | 0.490 |
Why?
|
ErbB Receptors | 5 | 2012 | 493 | 0.470 |
Why?
|
Nuclear Proteins | 6 | 2017 | 721 | 0.470 |
Why?
|
Breast Diseases | 4 | 2024 | 100 | 0.460 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2013 | 417 | 0.460 |
Why?
|
Quinazolines | 5 | 2015 | 220 | 0.460 |
Why?
|
Pathology | 1 | 2013 | 32 | 0.450 |
Why?
|
Protein-Arginine N-Methyltransferases | 1 | 2013 | 12 | 0.450 |
Why?
|
Computer-Assisted Instruction | 1 | 2013 | 44 | 0.450 |
Why?
|
Leukemia | 3 | 2014 | 321 | 0.450 |
Why?
|
Age Factors | 19 | 2019 | 1853 | 0.440 |
Why?
|
Base Sequence | 19 | 2016 | 2333 | 0.440 |
Why?
|
Gene Rearrangement | 6 | 2010 | 172 | 0.440 |
Why?
|
Chromosome Disorders | 4 | 2001 | 115 | 0.440 |
Why?
|
Postmenopause | 3 | 2013 | 99 | 0.440 |
Why?
|
Global Health | 3 | 2015 | 183 | 0.440 |
Why?
|
Chromosomes, Human, Pair 6 | 5 | 2019 | 125 | 0.440 |
Why?
|
Africa South of the Sahara | 4 | 2023 | 21 | 0.430 |
Why?
|
Reproductive Physiological Phenomena | 1 | 2012 | 4 | 0.430 |
Why?
|
Logistic Models | 12 | 2017 | 1200 | 0.430 |
Why?
|
Proto-Oncogene Proteins | 3 | 2011 | 655 | 0.430 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2012 | 48 | 0.420 |
Why?
|
Macrophages | 2 | 2013 | 571 | 0.420 |
Why?
|
Fanconi Anemia Complementation Group N Protein | 3 | 2019 | 14 | 0.420 |
Why?
|
Genes, myc | 2 | 2011 | 39 | 0.420 |
Why?
|
RNA, Messenger | 11 | 2022 | 1996 | 0.420 |
Why?
|
MCF-7 Cells | 7 | 2018 | 112 | 0.420 |
Why?
|
Epigenomics | 1 | 2013 | 103 | 0.420 |
Why?
|
DNA, Neoplasm | 7 | 2019 | 269 | 0.420 |
Why?
|
Lactation | 1 | 2012 | 53 | 0.420 |
Why?
|
Awareness | 1 | 2013 | 89 | 0.420 |
Why?
|
Waist-Hip Ratio | 1 | 2012 | 19 | 0.420 |
Why?
|
Adolescent | 27 | 2023 | 9111 | 0.420 |
Why?
|
Body Fat Distribution | 1 | 2012 | 13 | 0.410 |
Why?
|
Deoxycytidine | 1 | 2013 | 237 | 0.410 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2013 | 216 | 0.410 |
Why?
|
Delivery of Health Care | 2 | 2015 | 432 | 0.410 |
Why?
|
Surveys and Questionnaires | 9 | 2020 | 2574 | 0.410 |
Why?
|
Receptors, Androgen | 1 | 2012 | 119 | 0.400 |
Why?
|
Fluorouracil | 2 | 2013 | 558 | 0.400 |
Why?
|
Ambulatory Care Facilities | 1 | 2013 | 111 | 0.400 |
Why?
|
E-Box Elements | 1 | 2011 | 5 | 0.400 |
Why?
|
Estrogen Antagonists | 2 | 2011 | 48 | 0.400 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 5 | 2012 | 468 | 0.390 |
Why?
|
Cooking | 3 | 2017 | 55 | 0.390 |
Why?
|
Chromosomes, Human, Pair 17 | 4 | 2019 | 110 | 0.390 |
Why?
|
Biopsy | 7 | 2021 | 1181 | 0.390 |
Why?
|
Survival Rate | 11 | 2023 | 1877 | 0.380 |
Why?
|
Head and Neck Neoplasms | 6 | 2019 | 1057 | 0.380 |
Why?
|
Tumor Cells, Cultured | 21 | 2006 | 1049 | 0.380 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2011 | 52 | 0.380 |
Why?
|
ras Proteins | 1 | 2011 | 130 | 0.380 |
Why?
|
Prostatic Neoplasms | 8 | 2019 | 1759 | 0.370 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2011 | 146 | 0.370 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 4 | 2015 | 42 | 0.370 |
Why?
|
Fallopian Tubes | 3 | 2017 | 42 | 0.370 |
Why?
|
Gene Fusion | 1 | 2010 | 39 | 0.370 |
Why?
|
Chicago | 11 | 2021 | 1397 | 0.370 |
Why?
|
Urinary Bladder Neoplasms | 5 | 2001 | 392 | 0.370 |
Why?
|
Interdisciplinary Communication | 2 | 2012 | 130 | 0.360 |
Why?
|
Group Processes | 1 | 2010 | 31 | 0.360 |
Why?
|
Gene Frequency | 11 | 2016 | 682 | 0.360 |
Why?
|
Age of Onset | 13 | 2018 | 311 | 0.360 |
Why?
|
Quantitative Trait Loci | 8 | 2023 | 604 | 0.360 |
Why?
|
Community-Institutional Relations | 1 | 2010 | 29 | 0.360 |
Why?
|
Lung Neoplasms | 10 | 2023 | 2321 | 0.360 |
Why?
|
Homozygote | 7 | 2007 | 201 | 0.360 |
Why?
|
Cell Proliferation | 9 | 2019 | 1627 | 0.350 |
Why?
|
Contrast Media | 8 | 2020 | 1084 | 0.350 |
Why?
|
Molecular Sequence Data | 16 | 2012 | 3028 | 0.350 |
Why?
|
Prospective Studies | 16 | 2022 | 4247 | 0.350 |
Why?
|
Quality Improvement | 1 | 2013 | 433 | 0.340 |
Why?
|
Sequence Deletion | 7 | 2019 | 206 | 0.340 |
Why?
|
Family | 7 | 2018 | 316 | 0.340 |
Why?
|
Leukemia, Myeloid | 3 | 2004 | 249 | 0.340 |
Why?
|
DNA Copy Number Variations | 4 | 2022 | 175 | 0.340 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 1998 | 262 | 0.340 |
Why?
|
Endometrial Neoplasms | 3 | 2022 | 202 | 0.340 |
Why?
|
Mice | 19 | 2023 | 11619 | 0.340 |
Why?
|
Mendelian Randomization Analysis | 2 | 2019 | 44 | 0.330 |
Why?
|
Risk Reduction Behavior | 5 | 2014 | 96 | 0.330 |
Why?
|
Truth Disclosure | 3 | 2018 | 90 | 0.330 |
Why?
|
Complementary Therapies | 2 | 2023 | 56 | 0.330 |
Why?
|
Colonic Neoplasms | 3 | 2016 | 563 | 0.330 |
Why?
|
Antibodies, Monoclonal, Humanized | 3 | 2013 | 951 | 0.330 |
Why?
|
Trans-Activators | 5 | 2021 | 436 | 0.330 |
Why?
|
Linkage Disequilibrium | 9 | 2021 | 474 | 0.330 |
Why?
|
Information Storage and Retrieval | 2 | 2008 | 121 | 0.320 |
Why?
|
Carrier Proteins | 7 | 2016 | 677 | 0.320 |
Why?
|
Systems Integration | 1 | 2008 | 36 | 0.320 |
Why?
|
Database Management Systems | 1 | 2008 | 41 | 0.320 |
Why?
|
Aneuploidy | 2 | 2005 | 56 | 0.320 |
Why?
|
Universities | 3 | 2019 | 146 | 0.320 |
Why?
|
DNA Repair | 6 | 2014 | 359 | 0.310 |
Why?
|
Image Processing, Computer-Assisted | 6 | 2021 | 1225 | 0.310 |
Why?
|
Disclosure | 4 | 2020 | 109 | 0.310 |
Why?
|
Immunohistochemistry | 12 | 2022 | 1786 | 0.300 |
Why?
|
Allelic Imbalance | 3 | 2013 | 22 | 0.300 |
Why?
|
Cell Cycle Proteins | 5 | 2016 | 396 | 0.300 |
Why?
|
Patient Protection and Affordable Care Act | 2 | 2020 | 66 | 0.290 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2021 | 467 | 0.290 |
Why?
|
Gene Expression | 7 | 2018 | 1299 | 0.290 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2019 | 184 | 0.290 |
Why?
|
Bilirubin | 1 | 2007 | 130 | 0.290 |
Why?
|
Cameroon | 4 | 2024 | 16 | 0.290 |
Why?
|
Multigene Family | 6 | 2014 | 199 | 0.290 |
Why?
|
Computational Biology | 3 | 2016 | 536 | 0.290 |
Why?
|
Chromosomes, Human, Pair 7 | 2 | 2000 | 79 | 0.290 |
Why?
|
Capecitabine | 2 | 2020 | 98 | 0.290 |
Why?
|
Social Environment | 1 | 2008 | 187 | 0.280 |
Why?
|
Binding Sites | 7 | 2020 | 1107 | 0.280 |
Why?
|
Neoplasm Grading | 4 | 2021 | 366 | 0.280 |
Why?
|
Signal Transduction | 9 | 2018 | 3331 | 0.280 |
Why?
|
Schools, Medical | 2 | 2019 | 126 | 0.280 |
Why?
|
Genetics, Population | 4 | 2018 | 403 | 0.270 |
Why?
|
Hospitals, Teaching | 2 | 2018 | 117 | 0.270 |
Why?
|
Obesity | 3 | 2013 | 957 | 0.270 |
Why?
|
Pregnancy | 10 | 2018 | 2974 | 0.270 |
Why?
|
Cell Cycle | 2 | 2020 | 506 | 0.270 |
Why?
|
Quality of Health Care | 3 | 2017 | 384 | 0.270 |
Why?
|
Prevalence | 7 | 2021 | 1247 | 0.270 |
Why?
|
Interviews as Topic | 4 | 2018 | 333 | 0.270 |
Why?
|
Menarche | 2 | 2021 | 28 | 0.270 |
Why?
|
Phenotype | 10 | 2019 | 2424 | 0.260 |
Why?
|
Developing Countries | 2 | 2016 | 72 | 0.260 |
Why?
|
Multivariate Analysis | 10 | 2017 | 994 | 0.260 |
Why?
|
Brazil | 2 | 2022 | 69 | 0.260 |
Why?
|
Glioma | 5 | 1998 | 290 | 0.260 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2019 | 474 | 0.260 |
Why?
|
Depressive Disorder | 1 | 2006 | 223 | 0.250 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 2 | 2023 | 25 | 0.250 |
Why?
|
Community Participation | 2 | 2014 | 38 | 0.250 |
Why?
|
Polymerase Chain Reaction | 10 | 2011 | 927 | 0.250 |
Why?
|
Kaplan-Meier Estimate | 7 | 2023 | 858 | 0.250 |
Why?
|
Apoptosis | 4 | 2019 | 1705 | 0.250 |
Why?
|
Air Pollution, Indoor | 2 | 2017 | 63 | 0.250 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2015 | 1091 | 0.240 |
Why?
|
Family Health | 5 | 2011 | 162 | 0.240 |
Why?
|
RNA, Small Interfering | 4 | 2015 | 555 | 0.240 |
Why?
|
Multifactorial Inheritance | 4 | 2022 | 167 | 0.240 |
Why?
|
Weight Gain | 2 | 2021 | 121 | 0.240 |
Why?
|
Vulnerable Populations | 2 | 2020 | 79 | 0.240 |
Why?
|
Salpingostomy | 1 | 2004 | 1 | 0.240 |
Why?
|
Data Collection | 3 | 2023 | 374 | 0.240 |
Why?
|
Pseudogenes | 3 | 2021 | 34 | 0.240 |
Why?
|
Genetic Heterogeneity | 2 | 2021 | 62 | 0.240 |
Why?
|
Rosaniline Dyes | 1 | 2023 | 9 | 0.240 |
Why?
|
Copper | 2 | 2019 | 72 | 0.240 |
Why?
|
Population Surveillance | 4 | 2019 | 216 | 0.230 |
Why?
|
Whole Genome Sequencing | 2 | 2021 | 82 | 0.230 |
Why?
|
Databases, Genetic | 4 | 2019 | 263 | 0.230 |
Why?
|
Sequence Analysis, DNA | 7 | 2018 | 861 | 0.230 |
Why?
|
Animals | 20 | 2023 | 27028 | 0.230 |
Why?
|
Metformin | 2 | 2016 | 120 | 0.230 |
Why?
|
GATA3 Transcription Factor | 2 | 2021 | 48 | 0.230 |
Why?
|
Marital Status | 1 | 2023 | 42 | 0.230 |
Why?
|
Marketing of Health Services | 1 | 2003 | 15 | 0.230 |
Why?
|
Neoplasm, Residual | 2 | 2023 | 172 | 0.230 |
Why?
|
Cyclophosphamide | 4 | 2020 | 300 | 0.230 |
Why?
|
DNA Mismatch Repair | 2 | 2015 | 55 | 0.230 |
Why?
|
Epithelial-Mesenchymal Transition | 5 | 2014 | 94 | 0.220 |
Why?
|
Carcinoma, Lobular | 3 | 2014 | 81 | 0.220 |
Why?
|
Yoga | 1 | 2023 | 5 | 0.220 |
Why?
|
Meditation | 1 | 2023 | 5 | 0.220 |
Why?
|
Loss of Heterozygosity | 5 | 2016 | 86 | 0.220 |
Why?
|
Age Distribution | 4 | 2013 | 200 | 0.220 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 6 | 2013 | 888 | 0.220 |
Why?
|
Hypoglycemic Agents | 2 | 2016 | 342 | 0.210 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2015 | 160 | 0.210 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2023 | 475 | 0.210 |
Why?
|
Metabolome | 1 | 2023 | 51 | 0.210 |
Why?
|
Hematologic Neoplasms | 1 | 2006 | 335 | 0.210 |
Why?
|
Interferons | 6 | 1995 | 134 | 0.210 |
Why?
|
Pharmacists | 1 | 2022 | 32 | 0.210 |
Why?
|
Disease Progression | 8 | 2019 | 1479 | 0.210 |
Why?
|
Physician's Role | 2 | 2017 | 176 | 0.210 |
Why?
|
Synaptophysin | 1 | 2021 | 11 | 0.210 |
Why?
|
Mutation, Missense | 2 | 2007 | 276 | 0.210 |
Why?
|
Regulatory Sequences, Nucleic Acid | 3 | 2017 | 151 | 0.200 |
Why?
|
Social Class | 2 | 2016 | 134 | 0.200 |
Why?
|
Exome | 2 | 2019 | 127 | 0.200 |
Why?
|
Public Health | 2 | 2013 | 135 | 0.200 |
Why?
|
DNA Probes | 5 | 1997 | 77 | 0.200 |
Why?
|
Genes, p16 | 1 | 2001 | 11 | 0.200 |
Why?
|
DNA Helicases | 1 | 2022 | 84 | 0.200 |
Why?
|
Follow-Up Studies | 8 | 2020 | 3650 | 0.200 |
Why?
|
Oligonucleotide Array Sequence Analysis | 8 | 2009 | 696 | 0.200 |
Why?
|
Internationality | 2 | 2019 | 70 | 0.200 |
Why?
|
Microfilament Proteins | 2 | 2013 | 211 | 0.190 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2001 | 10 | 0.190 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2013 | 305 | 0.190 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2019 | 277 | 0.190 |
Why?
|
Needs Assessment | 1 | 2022 | 156 | 0.190 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 3 | 2010 | 12 | 0.190 |
Why?
|
Women's Health | 2 | 2018 | 102 | 0.190 |
Why?
|
RNA-Binding Proteins | 1 | 2003 | 256 | 0.190 |
Why?
|
Parent-Child Relations | 3 | 2012 | 79 | 0.190 |
Why?
|
Fourier Analysis | 4 | 2014 | 126 | 0.190 |
Why?
|
Myelodysplastic Syndromes | 2 | 2012 | 351 | 0.190 |
Why?
|
Chromosomes, Artificial, Yeast | 5 | 1995 | 37 | 0.190 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2001 | 51 | 0.190 |
Why?
|
Specimen Handling | 1 | 2021 | 101 | 0.190 |
Why?
|
Small Molecule Libraries | 2 | 2019 | 64 | 0.190 |
Why?
|
Tumor Escape | 1 | 2021 | 51 | 0.190 |
Why?
|
Telemedicine | 1 | 2023 | 176 | 0.190 |
Why?
|
Africa | 4 | 2021 | 101 | 0.190 |
Why?
|
Databases, Factual | 6 | 2017 | 839 | 0.190 |
Why?
|
Withholding Treatment | 1 | 2021 | 113 | 0.180 |
Why?
|
Microarray Analysis | 2 | 2018 | 96 | 0.180 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2021 | 121 | 0.180 |
Why?
|
Models, Organizational | 1 | 2020 | 47 | 0.180 |
Why?
|
Pregnancy Complications | 2 | 2018 | 343 | 0.180 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2001 | 166 | 0.180 |
Why?
|
NF-kappa B p50 Subunit | 1 | 2020 | 42 | 0.180 |
Why?
|
Echo-Planar Imaging | 4 | 2017 | 52 | 0.180 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2018 | 47 | 0.180 |
Why?
|
Neoplasm Metastasis | 4 | 2013 | 1094 | 0.180 |
Why?
|
Neoplasm Invasiveness | 5 | 2015 | 572 | 0.180 |
Why?
|
Water | 3 | 2012 | 284 | 0.180 |
Why?
|
Chromosomes, Human, Pair 12 | 2 | 2019 | 65 | 0.180 |
Why?
|
Gain of Function Mutation | 1 | 2019 | 13 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2000 | 192 | 0.180 |
Why?
|
Karyotyping | 7 | 2000 | 253 | 0.180 |
Why?
|
Poly (ADP-Ribose) Polymerase-1 | 1 | 2019 | 25 | 0.180 |
Why?
|
Trastuzumab | 3 | 2020 | 69 | 0.180 |
Why?
|
Survivorship | 1 | 2020 | 19 | 0.180 |
Why?
|
Gene Amplification | 5 | 2008 | 133 | 0.180 |
Why?
|
Fanconi Anemia Complementation Group C Protein | 1 | 2019 | 4 | 0.180 |
Why?
|
Image Enhancement | 4 | 2020 | 566 | 0.180 |
Why?
|
Health Occupations | 1 | 2019 | 5 | 0.170 |
Why?
|
Research Design | 5 | 2019 | 593 | 0.170 |
Why?
|
Nucleotidyltransferases | 1 | 2019 | 31 | 0.170 |
Why?
|
Noncommunicable Diseases | 1 | 2019 | 6 | 0.170 |
Why?
|
Interferon Type I | 2 | 1998 | 176 | 0.170 |
Why?
|
Arylamine N-Acetyltransferase | 1 | 2019 | 12 | 0.170 |
Why?
|
Patient Care Planning | 1 | 2020 | 81 | 0.170 |
Why?
|
Treatment Outcome | 10 | 2020 | 8104 | 0.170 |
Why?
|
Liver | 4 | 2013 | 1235 | 0.170 |
Why?
|
Population Groups | 1 | 2019 | 41 | 0.170 |
Why?
|
Apoptosis Regulatory Proteins | 3 | 2016 | 201 | 0.170 |
Why?
|
Algorithms | 8 | 2017 | 1857 | 0.170 |
Why?
|
Hospitals, University | 1 | 2020 | 195 | 0.170 |
Why?
|
Radiographic Image Enhancement | 2 | 2012 | 463 | 0.170 |
Why?
|
Drug Hypersensitivity | 1 | 2019 | 37 | 0.170 |
Why?
|
Chromosomes, Human, Pair 16 | 5 | 2013 | 79 | 0.170 |
Why?
|
Exercise | 2 | 2023 | 318 | 0.170 |
Why?
|
Pneumonia | 1 | 2001 | 182 | 0.170 |
Why?
|
High Mobility Group Proteins | 2 | 2016 | 26 | 0.170 |
Why?
|
Neoplastic Stem Cells | 2 | 2018 | 158 | 0.170 |
Why?
|
Interdisciplinary Studies | 1 | 2019 | 20 | 0.170 |
Why?
|
DNA Replication | 1 | 2019 | 168 | 0.170 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2019 | 114 | 0.170 |
Why?
|
Estrogen Replacement Therapy | 3 | 2013 | 45 | 0.160 |
Why?
|
Health Behavior | 3 | 2010 | 183 | 0.160 |
Why?
|
Sulfonamides | 2 | 2019 | 317 | 0.160 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2018 | 19 | 0.160 |
Why?
|
Pandemics | 2 | 2023 | 757 | 0.160 |
Why?
|
Inheritance Patterns | 1 | 2019 | 48 | 0.160 |
Why?
|
Cell Survival | 3 | 2019 | 977 | 0.160 |
Why?
|
Research Personnel | 1 | 2019 | 70 | 0.160 |
Why?
|
Protein Binding | 4 | 2016 | 1476 | 0.160 |
Why?
|
Time-to-Treatment | 1 | 2020 | 104 | 0.160 |
Why?
|
RNA Interference | 4 | 2015 | 373 | 0.160 |
Why?
|
Gene Dosage | 5 | 2011 | 208 | 0.160 |
Why?
|
PTEN Phosphohydrolase | 2 | 2014 | 135 | 0.160 |
Why?
|
Azacitidine | 3 | 2009 | 139 | 0.160 |
Why?
|
Homologous Recombination | 1 | 2018 | 51 | 0.160 |
Why?
|
Longitudinal Studies | 5 | 2023 | 1037 | 0.160 |
Why?
|
Image Interpretation, Computer-Assisted | 4 | 2017 | 681 | 0.160 |
Why?
|
Europe | 5 | 2021 | 313 | 0.160 |
Why?
|
Oxidative Stress | 2 | 2019 | 454 | 0.160 |
Why?
|
Cancer Survivors | 1 | 2020 | 92 | 0.160 |
Why?
|
Time Factors | 12 | 2015 | 5284 | 0.160 |
Why?
|
Occupations | 1 | 2017 | 25 | 0.150 |
Why?
|
Continuity of Patient Care | 1 | 2020 | 171 | 0.150 |
Why?
|
RNA, Neoplasm | 1 | 2018 | 88 | 0.150 |
Why?
|
Haptoglobins | 1 | 2017 | 9 | 0.150 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2017 | 294 | 0.150 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 201 | 0.150 |
Why?
|
Patient Preference | 1 | 2018 | 108 | 0.150 |
Why?
|
Adenomatous Polyposis Coli | 2 | 2012 | 39 | 0.150 |
Why?
|
Cell Line | 7 | 2016 | 2491 | 0.150 |
Why?
|
Cell Movement | 2 | 2019 | 780 | 0.150 |
Why?
|
Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2017 | 9 | 0.150 |
Why?
|
Combined Modality Therapy | 5 | 2023 | 1703 | 0.150 |
Why?
|
Human Genome Project | 1 | 1997 | 19 | 0.150 |
Why?
|
Hydroxamic Acids | 2 | 2009 | 50 | 0.150 |
Why?
|
3' Untranslated Regions | 3 | 2019 | 94 | 0.150 |
Why?
|
Genetic Markers | 5 | 2008 | 476 | 0.150 |
Why?
|
Ovary | 1 | 2019 | 261 | 0.150 |
Why?
|
Asthma | 2 | 2019 | 971 | 0.150 |
Why?
|
Lymphatic Metastasis | 6 | 2018 | 498 | 0.150 |
Why?
|
Barbados | 2 | 2018 | 7 | 0.150 |
Why?
|
Medical Order Entry Systems | 1 | 2017 | 25 | 0.150 |
Why?
|
Carboplatin | 2 | 2016 | 302 | 0.150 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 168 | 0.150 |
Why?
|
Communication | 2 | 2018 | 448 | 0.150 |
Why?
|
DNA Glycosylases | 2 | 2014 | 25 | 0.150 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2017 | 64 | 0.150 |
Why?
|
Cystadenocarcinoma, Serous | 2 | 2016 | 48 | 0.150 |
Why?
|
Maternal Exposure | 1 | 2017 | 58 | 0.140 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 225 | 0.140 |
Why?
|
Polycomb Repressive Complex 2 | 2 | 2014 | 31 | 0.140 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 1996 | 6 | 0.140 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 1995 | 393 | 0.140 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2016 | 54 | 0.140 |
Why?
|
Placenta Growth Factor | 1 | 2017 | 70 | 0.140 |
Why?
|
Practice Guidelines as Topic | 3 | 2019 | 1024 | 0.140 |
Why?
|
Body Weights and Measures | 2 | 2021 | 27 | 0.140 |
Why?
|
Gene-Environment Interaction | 1 | 2018 | 109 | 0.140 |
Why?
|
Human Migration | 1 | 2016 | 26 | 0.140 |
Why?
|
Patient-Centered Care | 1 | 2019 | 206 | 0.140 |
Why?
|
Ribonuclease III | 1 | 2016 | 16 | 0.140 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2016 | 59 | 0.140 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 1998 | 154 | 0.140 |
Why?
|
Decision Support Systems, Clinical | 1 | 2017 | 105 | 0.140 |
Why?
|
Homeodomain Proteins | 1 | 2020 | 544 | 0.140 |
Why?
|
Decanoic Acids | 1 | 2016 | 11 | 0.140 |
Why?
|
Education, Medical, Undergraduate | 1 | 2019 | 169 | 0.140 |
Why?
|
Interleukin-11 | 2 | 2013 | 20 | 0.140 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2017 | 92 | 0.140 |
Why?
|
Glycolysis | 1 | 2017 | 133 | 0.140 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 144 | 0.140 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 5 | 2008 | 1100 | 0.140 |
Why?
|
Vidarabine | 1 | 1996 | 143 | 0.140 |
Why?
|
Placenta | 1 | 2017 | 178 | 0.140 |
Why?
|
Leuprolide | 1 | 2016 | 34 | 0.140 |
Why?
|
Cell Transformation, Neoplastic | 2 | 1998 | 447 | 0.140 |
Why?
|
Carmustine | 1 | 2016 | 70 | 0.140 |
Why?
|
Leukemia, Radiation-Induced | 1 | 2015 | 14 | 0.140 |
Why?
|
Air Pollution | 1 | 2017 | 79 | 0.140 |
Why?
|
Codon, Terminator | 1 | 2015 | 22 | 0.140 |
Why?
|
Internal-External Control | 1 | 2016 | 45 | 0.140 |
Why?
|
Information Management | 1 | 2015 | 7 | 0.140 |
Why?
|
Polyesters | 1 | 2016 | 41 | 0.140 |
Why?
|
Carcinosarcoma | 1 | 2016 | 21 | 0.130 |
Why?
|
Cell Nucleus | 2 | 2021 | 590 | 0.130 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2015 | 309 | 0.130 |
Why?
|
Gene Flow | 1 | 2016 | 90 | 0.130 |
Why?
|
Quality of Life | 2 | 2021 | 1638 | 0.130 |
Why?
|
Drug Prescriptions | 1 | 2017 | 144 | 0.130 |
Why?
|
Cloning, Molecular | 3 | 1995 | 647 | 0.130 |
Why?
|
Epithelial Cells | 3 | 2017 | 685 | 0.130 |
Why?
|
Internal Medicine | 2 | 2009 | 356 | 0.130 |
Why?
|
Religion | 1 | 2016 | 88 | 0.130 |
Why?
|
Benzimidazoles | 1 | 2016 | 113 | 0.130 |
Why?
|
Genes, Mitochondrial | 1 | 2015 | 10 | 0.130 |
Why?
|
Incidence | 8 | 2015 | 1580 | 0.130 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2016 | 62 | 0.130 |
Why?
|
Guideline Adherence | 1 | 2017 | 226 | 0.130 |
Why?
|
Craniotomy | 1 | 2016 | 88 | 0.130 |
Why?
|
Nitriles | 1 | 2016 | 157 | 0.130 |
Why?
|
Triazoles | 1 | 2016 | 99 | 0.130 |
Why?
|
Transcription, Genetic | 3 | 2009 | 1144 | 0.130 |
Why?
|
Health Services Needs and Demand | 2 | 2013 | 103 | 0.130 |
Why?
|
Lymph Nodes | 2 | 2009 | 546 | 0.130 |
Why?
|
Lymphoid Enhancer-Binding Factor 1 | 1 | 2015 | 13 | 0.130 |
Why?
|
Insulin-Like Growth Factor II | 2 | 2013 | 33 | 0.130 |
Why?
|
Vitamin D | 1 | 2017 | 264 | 0.130 |
Why?
|
Cyclin-Dependent Kinases | 1 | 1995 | 43 | 0.130 |
Why?
|
Sensitivity and Specificity | 8 | 2014 | 2019 | 0.130 |
Why?
|
Health Surveys | 2 | 2021 | 239 | 0.130 |
Why?
|
Telephone | 3 | 2020 | 35 | 0.130 |
Why?
|
Vimentin | 2 | 2012 | 45 | 0.130 |
Why?
|
Immunoenzyme Techniques | 2 | 2012 | 306 | 0.130 |
Why?
|
Pilot Projects | 5 | 2022 | 861 | 0.130 |
Why?
|
Cadherins | 2 | 2018 | 159 | 0.130 |
Why?
|
Enhancer Elements, Genetic | 3 | 2016 | 277 | 0.130 |
Why?
|
Wnt Proteins | 2 | 2018 | 130 | 0.120 |
Why?
|
Insulin Receptor Substrate Proteins | 2 | 2012 | 55 | 0.120 |
Why?
|
Terminology as Topic | 2 | 2015 | 219 | 0.120 |
Why?
|
Bone Marrow | 2 | 1995 | 440 | 0.120 |
Why?
|
Chromosome Banding | 3 | 2004 | 74 | 0.120 |
Why?
|
Health Literacy | 1 | 2016 | 71 | 0.120 |
Why?
|
Registries | 6 | 2021 | 743 | 0.120 |
Why?
|
Interprofessional Relations | 2 | 2019 | 123 | 0.120 |
Why?
|
Genes, Reporter | 2 | 2015 | 272 | 0.120 |
Why?
|
Social Isolation | 2 | 2021 | 67 | 0.120 |
Why?
|
Mammary Glands, Human | 1 | 2014 | 22 | 0.120 |
Why?
|
Cytoskeleton | 2 | 2013 | 194 | 0.120 |
Why?
|
Laboratories | 2 | 2013 | 43 | 0.120 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2004 | 779 | 0.120 |
Why?
|
Biomarkers | 4 | 2017 | 1744 | 0.120 |
Why?
|
ROC Curve | 7 | 2012 | 769 | 0.120 |
Why?
|
Curriculum | 1 | 2019 | 556 | 0.120 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2014 | 102 | 0.120 |
Why?
|
Health Care Reform | 1 | 2015 | 86 | 0.120 |
Why?
|
Oncogenes | 1 | 2014 | 90 | 0.120 |
Why?
|
Transcription Factor 7-Like 1 Protein | 1 | 2013 | 8 | 0.110 |
Why?
|
Primary Prevention | 2 | 2014 | 79 | 0.110 |
Why?
|
Predictive Value of Tests | 7 | 2020 | 1697 | 0.110 |
Why?
|
Students, Medical | 1 | 2019 | 409 | 0.110 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2013 | 27 | 0.110 |
Why?
|
Phytotherapy | 1 | 2014 | 134 | 0.110 |
Why?
|
Nerve Tissue Proteins | 2 | 2010 | 508 | 0.110 |
Why?
|
Tissue Array Analysis | 1 | 2013 | 127 | 0.110 |
Why?
|
Chemoradiotherapy | 1 | 2016 | 305 | 0.110 |
Why?
|
Epidemiologic Studies | 1 | 2013 | 16 | 0.110 |
Why?
|
Qualitative Research | 1 | 2014 | 279 | 0.110 |
Why?
|
Breast Self-Examination | 1 | 2013 | 3 | 0.110 |
Why?
|
Communications Media | 1 | 2013 | 2 | 0.110 |
Why?
|
Computer Simulation | 4 | 2018 | 1092 | 0.110 |
Why?
|
Alcohol Oxidoreductases | 1 | 2013 | 17 | 0.110 |
Why?
|
Practice Patterns, Physicians' | 1 | 2018 | 593 | 0.110 |
Why?
|
Smoke | 1 | 2013 | 27 | 0.110 |
Why?
|
Feasibility Studies | 2 | 2013 | 769 | 0.110 |
Why?
|
Inhalation Exposure | 1 | 2013 | 30 | 0.110 |
Why?
|
Rescue Work | 1 | 2012 | 7 | 0.110 |
Why?
|
Relief Work | 1 | 2012 | 7 | 0.110 |
Why?
|
Drug Administration Schedule | 3 | 2010 | 900 | 0.110 |
Why?
|
Informed Consent | 2 | 2014 | 272 | 0.110 |
Why?
|
Epithelium | 2 | 2013 | 322 | 0.110 |
Why?
|
Earthquakes | 1 | 2012 | 12 | 0.110 |
Why?
|
Mass Casualty Incidents | 1 | 2012 | 13 | 0.110 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 1992 | 30 | 0.110 |
Why?
|
Sequence Homology, Amino Acid | 3 | 2006 | 416 | 0.110 |
Why?
|
Disasters | 1 | 2012 | 21 | 0.110 |
Why?
|
Altruism | 1 | 2012 | 35 | 0.110 |
Why?
|
Cooperative Behavior | 2 | 2012 | 179 | 0.110 |
Why?
|
Tanzania | 1 | 2012 | 46 | 0.110 |
Why?
|
Radiosurgery | 1 | 2016 | 274 | 0.110 |
Why?
|
History, 20th Century | 1 | 2014 | 307 | 0.110 |
Why?
|
Wnt Signaling Pathway | 1 | 2013 | 96 | 0.110 |
Why?
|
Carcinoma, Small Cell | 1 | 1993 | 133 | 0.110 |
Why?
|
Drug Discovery | 2 | 2015 | 106 | 0.110 |
Why?
|
Carcinoma in Situ | 1 | 2012 | 54 | 0.110 |
Why?
|
Cytoplasm | 1 | 2013 | 284 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 3 | 2018 | 61 | 0.100 |
Why?
|
Hypoxia | 1 | 2017 | 649 | 0.100 |
Why?
|
Chromatin Immunoprecipitation | 2 | 2010 | 136 | 0.100 |
Why?
|
Waist Circumference | 1 | 2012 | 21 | 0.100 |
Why?
|
Patient Acceptance of Health Care | 1 | 2014 | 252 | 0.100 |
Why?
|
Cancer Care Facilities | 2 | 2015 | 29 | 0.100 |
Why?
|
Quality Assurance, Health Care | 1 | 2013 | 222 | 0.100 |
Why?
|
Kisspeptins | 1 | 2011 | 4 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 3 | 2011 | 599 | 0.100 |
Why?
|
DNA, Complementary | 3 | 2007 | 394 | 0.100 |
Why?
|
Observer Variation | 1 | 2013 | 607 | 0.100 |
Why?
|
Mastectomy, Segmental | 2 | 2017 | 93 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2012 | 1939 | 0.100 |
Why?
|
Models, Theoretical | 1 | 2014 | 489 | 0.100 |
Why?
|
Mutation Rate | 1 | 2012 | 48 | 0.100 |
Why?
|
Organoplatinum Compounds | 1 | 2011 | 96 | 0.100 |
Why?
|
Alcohol Drinking | 1 | 2014 | 273 | 0.100 |
Why?
|
Microsatellite Instability | 1 | 2011 | 46 | 0.100 |
Why?
|
Extracellular Matrix | 1 | 2013 | 242 | 0.100 |
Why?
|
Polychondritis, Relapsing | 1 | 2011 | 5 | 0.100 |
Why?
|
DNA, Recombinant | 1 | 2011 | 67 | 0.100 |
Why?
|
Bayes Theorem | 3 | 2022 | 366 | 0.100 |
Why?
|
Codon, Nonsense | 1 | 2011 | 42 | 0.100 |
Why?
|
Consensus Sequence | 1 | 2011 | 65 | 0.100 |
Why?
|
Telomerase | 1 | 2011 | 59 | 0.100 |
Why?
|
Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2011 | 5 | 0.100 |
Why?
|
Lymphocytes | 4 | 2005 | 469 | 0.100 |
Why?
|
Deafness | 1 | 2011 | 47 | 0.100 |
Why?
|
Pericardial Effusion | 1 | 1991 | 20 | 0.100 |
Why?
|
Stomach Neoplasms | 2 | 2011 | 268 | 0.100 |
Why?
|
Thyroid Neoplasms | 1 | 2016 | 414 | 0.100 |
Why?
|
Health Promotion | 1 | 2013 | 158 | 0.100 |
Why?
|
Pleural Effusion | 1 | 1991 | 47 | 0.100 |
Why?
|
Internet | 1 | 2013 | 317 | 0.100 |
Why?
|
Contraceptives, Oral | 2 | 2020 | 46 | 0.100 |
Why?
|
Arthritis | 1 | 2011 | 47 | 0.100 |
Why?
|
Regulatory Elements, Transcriptional | 1 | 2011 | 45 | 0.100 |
Why?
|
Mice, Nude | 4 | 2019 | 810 | 0.090 |
Why?
|
Radiotherapy | 2 | 2011 | 331 | 0.090 |
Why?
|
Parents | 2 | 2012 | 281 | 0.090 |
Why?
|
Ataxin-7 | 1 | 2010 | 5 | 0.090 |
Why?
|
Poverty | 2 | 2013 | 178 | 0.090 |
Why?
|
Lung Diseases | 1 | 2013 | 267 | 0.090 |
Why?
|
Serine Endopeptidases | 1 | 2011 | 145 | 0.090 |
Why?
|
Chromosome Breakpoints | 1 | 2010 | 15 | 0.090 |
Why?
|
Heredity | 1 | 2010 | 19 | 0.090 |
Why?
|
Diabetes Complications | 1 | 2012 | 172 | 0.090 |
Why?
|
Protein Isoforms | 1 | 2011 | 273 | 0.090 |
Why?
|
Minors | 1 | 2010 | 15 | 0.090 |
Why?
|
Rad51 Recombinase | 2 | 2009 | 80 | 0.090 |
Why?
|
Histones | 2 | 2013 | 322 | 0.090 |
Why?
|
HIV Infections | 1 | 2019 | 827 | 0.090 |
Why?
|
Interinstitutional Relations | 1 | 2010 | 29 | 0.090 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 156 | 0.090 |
Why?
|
Repressor Proteins | 2 | 2011 | 415 | 0.090 |
Why?
|
Hodgkin Disease | 1 | 2011 | 180 | 0.090 |
Why?
|
Blotting, Southern | 3 | 1995 | 129 | 0.090 |
Why?
|
SEER Program | 2 | 2014 | 196 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2012 | 382 | 0.090 |
Why?
|
Taxoids | 3 | 2020 | 130 | 0.090 |
Why?
|
Models, Genetic | 4 | 2018 | 941 | 0.090 |
Why?
|
Senegal | 1 | 2009 | 4 | 0.090 |
Why?
|
Hypersensitivity | 1 | 2011 | 158 | 0.090 |
Why?
|
Restriction Mapping | 3 | 1995 | 157 | 0.090 |
Why?
|
Emergency Medical Services | 1 | 2012 | 210 | 0.090 |
Why?
|
Fatal Outcome | 3 | 2001 | 295 | 0.090 |
Why?
|
Aromatase Inhibitors | 1 | 2009 | 29 | 0.090 |
Why?
|
RNA Splice Sites | 2 | 2016 | 56 | 0.090 |
Why?
|
Amino Acid Sequence | 3 | 2006 | 2061 | 0.090 |
Why?
|
Health Services Research | 1 | 2010 | 137 | 0.090 |
Why?
|
Transfection | 1 | 2011 | 907 | 0.090 |
Why?
|
Adult Children | 1 | 2009 | 12 | 0.080 |
Why?
|
Genes, p53 | 2 | 2001 | 109 | 0.080 |
Why?
|
Somatomedins | 1 | 2009 | 28 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 22 | 0.080 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 1 | 2009 | 60 | 0.080 |
Why?
|
Cluster Analysis | 4 | 2013 | 369 | 0.080 |
Why?
|
Acute Disease | 3 | 2004 | 838 | 0.080 |
Why?
|
Online Systems | 1 | 2008 | 24 | 0.080 |
Why?
|
Models, Statistical | 2 | 2018 | 575 | 0.080 |
Why?
|
Skin | 1 | 2012 | 570 | 0.080 |
Why?
|
Esophageal Neoplasms | 1 | 2011 | 329 | 0.080 |
Why?
|
Urban Health | 2 | 2011 | 55 | 0.080 |
Why?
|
MAP Kinase Kinase Kinase 1 | 1 | 2008 | 10 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 5 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Protein 5 | 1 | 2008 | 7 | 0.080 |
Why?
|
Recurrence | 4 | 2018 | 1168 | 0.080 |
Why?
|
Confidence Intervals | 3 | 2013 | 225 | 0.080 |
Why?
|
International Classification of Diseases | 1 | 2008 | 69 | 0.080 |
Why?
|
DNA Repair Enzymes | 3 | 2015 | 55 | 0.080 |
Why?
|
Chromosomes, Human, Pair 8 | 3 | 2019 | 85 | 0.080 |
Why?
|
Anticarcinogenic Agents | 2 | 2000 | 71 | 0.080 |
Why?
|
Pyrazines | 2 | 2000 | 92 | 0.080 |
Why?
|
Lysine | 2 | 2020 | 149 | 0.080 |
Why?
|
Phantoms, Imaging | 1 | 2010 | 450 | 0.070 |
Why?
|
Health Status Indicators | 1 | 2008 | 104 | 0.070 |
Why?
|
Dinucleotide Repeats | 1 | 2007 | 14 | 0.070 |
Why?
|
Diabetes Mellitus | 1 | 2014 | 743 | 0.070 |
Why?
|
Child | 8 | 2013 | 7065 | 0.070 |
Why?
|
Medically Uninsured | 1 | 2007 | 59 | 0.070 |
Why?
|
Probability | 2 | 2005 | 356 | 0.070 |
Why?
|
Inflammation | 1 | 2013 | 951 | 0.070 |
Why?
|
Hot Temperature | 2 | 2005 | 206 | 0.070 |
Why?
|
Receptors, Glucocorticoid | 1 | 2008 | 129 | 0.070 |
Why?
|
Chromosomes, Human, Pair 2 | 3 | 2016 | 85 | 0.070 |
Why?
|
User-Computer Interface | 1 | 2008 | 187 | 0.070 |
Why?
|
Estrogens | 1 | 2008 | 201 | 0.070 |
Why?
|
Methylation | 2 | 2013 | 263 | 0.070 |
Why?
|
Datasets as Topic | 2 | 2019 | 76 | 0.070 |
Why?
|
T-Lymphocytes | 1 | 2013 | 1209 | 0.070 |
Why?
|
Urban Population | 2 | 2020 | 221 | 0.070 |
Why?
|
Chromatin | 3 | 2013 | 393 | 0.070 |
Why?
|
Research Support as Topic | 2 | 2019 | 82 | 0.070 |
Why?
|
Geography | 2 | 2018 | 228 | 0.070 |
Why?
|
Genes, APC | 1 | 2006 | 26 | 0.070 |
Why?
|
Abortion, Therapeutic | 1 | 2006 | 11 | 0.070 |
Why?
|
Genes, Neoplasm | 1 | 2006 | 37 | 0.070 |
Why?
|
Subtraction Technique | 1 | 2006 | 132 | 0.070 |
Why?
|
Neovascularization, Physiologic | 1 | 2007 | 142 | 0.070 |
Why?
|
Carcinogenesis | 2 | 2018 | 204 | 0.070 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2006 | 49 | 0.070 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2007 | 125 | 0.070 |
Why?
|
Breast Density | 2 | 2017 | 31 | 0.070 |
Why?
|
Gene Expression Regulation | 2 | 2010 | 1956 | 0.070 |
Why?
|
Child Development | 1 | 2007 | 167 | 0.070 |
Why?
|
Paraffin Embedding | 1 | 2005 | 78 | 0.070 |
Why?
|
Microwaves | 1 | 2005 | 36 | 0.070 |
Why?
|
Conserved Sequence | 1 | 2006 | 210 | 0.070 |
Why?
|
Abortion, Spontaneous | 1 | 2006 | 66 | 0.070 |
Why?
|
Statistics as Topic | 1 | 2006 | 235 | 0.060 |
Why?
|
Tissue Culture Techniques | 1 | 2005 | 81 | 0.060 |
Why?
|
Imaging, Three-Dimensional | 1 | 2009 | 588 | 0.060 |
Why?
|
Postpartum Period | 2 | 2018 | 138 | 0.060 |
Why?
|
Structure-Activity Relationship | 1 | 2006 | 411 | 0.060 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 3 | 1995 | 20 | 0.060 |
Why?
|
NAD(P)H Dehydrogenase (Quinone) | 1 | 2004 | 9 | 0.060 |
Why?
|
Discriminant Analysis | 2 | 2007 | 67 | 0.060 |
Why?
|
Choice Behavior | 1 | 2006 | 160 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2011 | 1212 | 0.060 |
Why?
|
Ethanol | 2 | 2017 | 250 | 0.060 |
Why?
|
Hormone Replacement Therapy | 1 | 2005 | 78 | 0.060 |
Why?
|
Attitude to Health | 1 | 2006 | 221 | 0.060 |
Why?
|
Culture | 1 | 2005 | 53 | 0.060 |
Why?
|
Disease Susceptibility | 2 | 2018 | 198 | 0.060 |
Why?
|
Down-Regulation | 3 | 2015 | 513 | 0.060 |
Why?
|
Adipose Tissue | 1 | 2006 | 247 | 0.060 |
Why?
|
Smoking | 2 | 2019 | 617 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2007 | 320 | 0.060 |
Why?
|
Software | 3 | 2017 | 661 | 0.060 |
Why?
|
Protein Structure, Tertiary | 1 | 2006 | 738 | 0.060 |
Why?
|
MutL Protein Homolog 1 | 2 | 2015 | 33 | 0.060 |
Why?
|
MutS Homolog 2 Protein | 2 | 2015 | 30 | 0.060 |
Why?
|
Enhancer of Zeste Homolog 2 Protein | 2 | 2014 | 36 | 0.060 |
Why?
|
North America | 3 | 2011 | 184 | 0.060 |
Why?
|
Peptide Synthases | 1 | 2003 | 12 | 0.060 |
Why?
|
Raloxifene Hydrochloride | 1 | 2023 | 10 | 0.060 |
Why?
|
Vincristine | 2 | 1996 | 112 | 0.060 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2014 | 73 | 0.060 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 154 | 0.060 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 1157 | 0.060 |
Why?
|
Antigens, CD | 2 | 2018 | 462 | 0.060 |
Why?
|
Personal Satisfaction | 1 | 2023 | 62 | 0.060 |
Why?
|
International Cooperation | 2 | 2014 | 123 | 0.050 |
Why?
|
Prednisone | 2 | 1996 | 258 | 0.050 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2002 | 18 | 0.050 |
Why?
|
Genetic Linkage | 2 | 2004 | 623 | 0.050 |
Why?
|
Metabolomics | 1 | 2023 | 71 | 0.050 |
Why?
|
DNA Primers | 6 | 2007 | 544 | 0.050 |
Why?
|
Hormones | 1 | 2023 | 140 | 0.050 |
Why?
|
Counseling | 1 | 2023 | 159 | 0.050 |
Why?
|
Cyclin D1 | 1 | 2002 | 84 | 0.050 |
Why?
|
Child, Preschool | 4 | 2010 | 3661 | 0.050 |
Why?
|
International Agencies | 2 | 2014 | 34 | 0.050 |
Why?
|
Genes, Dominant | 2 | 2004 | 117 | 0.050 |
Why?
|
Data Accuracy | 1 | 2021 | 31 | 0.050 |
Why?
|
Sendai virus | 1 | 2021 | 8 | 0.050 |
Why?
|
Respirovirus Infections | 1 | 2021 | 12 | 0.050 |
Why?
|
Tertiary Care Centers | 1 | 2021 | 99 | 0.050 |
Why?
|
Retinoblastoma Protein | 1 | 2001 | 67 | 0.050 |
Why?
|
Transcription Factor RelA | 1 | 2021 | 49 | 0.050 |
Why?
|
Canada | 2 | 2015 | 206 | 0.050 |
Why?
|
Primary Cell Culture | 1 | 2021 | 74 | 0.050 |
Why?
|
DNA Damage | 2 | 2019 | 371 | 0.050 |
Why?
|
Protective Factors | 1 | 2020 | 23 | 0.050 |
Why?
|
Gene Knockout Techniques | 1 | 2021 | 79 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2005 | 320 | 0.050 |
Why?
|
Acid Anhydride Hydrolases | 2 | 2011 | 13 | 0.050 |
Why?
|
Bridged-Ring Compounds | 1 | 2020 | 13 | 0.050 |
Why?
|
Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
Ubiquitination | 1 | 2020 | 70 | 0.050 |
Why?
|
Phylogeny | 2 | 2016 | 1156 | 0.050 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 27 | 0.050 |
Why?
|
Mice, Inbred C3H | 1 | 2020 | 371 | 0.050 |
Why?
|
Serine | 1 | 2020 | 102 | 0.050 |
Why?
|
Genetic Research | 2 | 1997 | 17 | 0.050 |
Why?
|
Minichromosome Maintenance Complex Component 2 | 1 | 2019 | 2 | 0.040 |
Why?
|
Melanoma | 2 | 1995 | 462 | 0.040 |
Why?
|
Protein Domains | 1 | 2020 | 131 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2023 | 458 | 0.040 |
Why?
|
Evolution, Molecular | 1 | 2006 | 829 | 0.040 |
Why?
|
Patient Reported Outcome Measures | 1 | 2021 | 186 | 0.040 |
Why?
|
Zinc Finger E-box-Binding Homeobox 1 | 1 | 2019 | 4 | 0.040 |
Why?
|
Genotyping Techniques | 1 | 2020 | 69 | 0.040 |
Why?
|
Computers | 1 | 2000 | 112 | 0.040 |
Why?
|
Fanconi Anemia | 1 | 2019 | 9 | 0.040 |
Why?
|
Glutathione Transferase | 2 | 2000 | 112 | 0.040 |
Why?
|
Bronchi | 1 | 2001 | 231 | 0.040 |
Why?
|
Africa, Northern | 1 | 2019 | 5 | 0.040 |
Why?
|
Glutathione | 2 | 2000 | 108 | 0.040 |
Why?
|
Middle East | 1 | 2019 | 18 | 0.040 |
Why?
|
Biophysical Phenomena | 1 | 2000 | 123 | 0.040 |
Why?
|
Interferon-alpha | 2 | 1998 | 234 | 0.040 |
Why?
|
Propensity Score | 1 | 2020 | 143 | 0.040 |
Why?
|
Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2019 | 18 | 0.040 |
Why?
|
Biophysics | 1 | 2000 | 153 | 0.040 |
Why?
|
Colonic Polyps | 1 | 2000 | 128 | 0.040 |
Why?
|
Academies and Institutes | 1 | 2019 | 31 | 0.040 |
Why?
|
Chi-Square Distribution | 2 | 2015 | 360 | 0.040 |
Why?
|
HIV | 1 | 2019 | 48 | 0.040 |
Why?
|
Data Mining | 1 | 2019 | 42 | 0.040 |
Why?
|
Menopause | 1 | 2019 | 75 | 0.040 |
Why?
|
Haploinsufficiency | 1 | 2019 | 63 | 0.040 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2019 | 96 | 0.040 |
Why?
|
APOBEC Deaminases | 1 | 2018 | 5 | 0.040 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2019 | 138 | 0.040 |
Why?
|
China | 1 | 2019 | 230 | 0.040 |
Why?
|
Antiphospholipid Syndrome | 1 | 1999 | 20 | 0.040 |
Why?
|
Population Health | 1 | 2019 | 33 | 0.040 |
Why?
|
Palpation | 1 | 2018 | 18 | 0.040 |
Why?
|
Plasma Exchange | 1 | 1999 | 30 | 0.040 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 1999 | 118 | 0.040 |
Why?
|
Codon | 1 | 1999 | 123 | 0.040 |
Why?
|
Pregnancy Trimester, Third | 1 | 2018 | 70 | 0.040 |
Why?
|
Cells, Cultured | 3 | 2007 | 2844 | 0.040 |
Why?
|
Genomic Library | 2 | 1995 | 33 | 0.040 |
Why?
|
Regression Analysis | 1 | 2000 | 594 | 0.040 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 1998 | 41 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2019 | 370 | 0.040 |
Why?
|
Protein Processing, Post-Translational | 1 | 2020 | 378 | 0.040 |
Why?
|
Image-Guided Biopsy | 1 | 2018 | 66 | 0.040 |
Why?
|
Penetrance | 1 | 2018 | 44 | 0.040 |
Why?
|
Biological Transport | 2 | 2010 | 399 | 0.040 |
Why?
|
Models, Biological | 2 | 2008 | 1759 | 0.040 |
Why?
|
Receptors, Notch | 1 | 2018 | 123 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2018 | 396 | 0.040 |
Why?
|
Cell Hypoxia | 1 | 2018 | 170 | 0.040 |
Why?
|
Ultrasonography, Mammary | 1 | 2018 | 83 | 0.040 |
Why?
|
Medicare | 1 | 2021 | 417 | 0.040 |
Why?
|
American Cancer Society | 1 | 1997 | 13 | 0.040 |
Why?
|
Diagnosis, Differential | 3 | 2009 | 1586 | 0.040 |
Why?
|
Genes, bcl-2 | 1 | 1997 | 16 | 0.040 |
Why?
|
Asia | 1 | 2017 | 99 | 0.040 |
Why?
|
Physical Examination | 1 | 2018 | 148 | 0.040 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 1998 | 79 | 0.040 |
Why?
|
Fibroblasts | 1 | 2020 | 736 | 0.040 |
Why?
|
Mixed Function Oxygenases | 1 | 1998 | 68 | 0.040 |
Why?
|
Autoantibodies | 1 | 1999 | 267 | 0.040 |
Why?
|
Glycoproteins | 1 | 1999 | 235 | 0.040 |
Why?
|
bcl-X Protein | 1 | 1997 | 53 | 0.040 |
Why?
|
Purines | 1 | 1997 | 91 | 0.040 |
Why?
|
Telomere-Binding Proteins | 1 | 2017 | 14 | 0.040 |
Why?
|
Cell Differentiation | 2 | 2014 | 1501 | 0.040 |
Why?
|
Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2021 | 424 | 0.040 |
Why?
|
Patient Compliance | 1 | 2018 | 228 | 0.040 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2017 | 32 | 0.040 |
Why?
|
Nucleic Acid Hybridization | 1 | 1997 | 245 | 0.040 |
Why?
|
HL-60 Cells | 1 | 1997 | 20 | 0.040 |
Why?
|
Comorbidity | 1 | 2021 | 941 | 0.040 |
Why?
|
DNA | 2 | 2001 | 1306 | 0.040 |
Why?
|
Organizational Policy | 1 | 1997 | 55 | 0.040 |
Why?
|
Meta-Analysis as Topic | 1 | 2017 | 86 | 0.040 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 1073 | 0.040 |
Why?
|
Educational Measurement | 1 | 2019 | 230 | 0.040 |
Why?
|
Fetal Blood | 1 | 2017 | 90 | 0.040 |
Why?
|
Health Care Costs | 1 | 2019 | 232 | 0.040 |
Why?
|
Federal Government | 1 | 1996 | 29 | 0.040 |
Why?
|
Empirical Research | 1 | 1996 | 19 | 0.040 |
Why?
|
DNA, Intergenic | 1 | 2016 | 26 | 0.040 |
Why?
|
Cytokines | 1 | 2021 | 795 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2009 | 2740 | 0.040 |
Why?
|
Chemoprevention | 1 | 2017 | 92 | 0.040 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2016 | 106 | 0.040 |
Why?
|
Neuroblastoma | 1 | 2020 | 389 | 0.040 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1998 | 172 | 0.040 |
Why?
|
Tumor Burden | 1 | 2018 | 301 | 0.040 |
Why?
|
Cyclophilins | 1 | 2016 | 8 | 0.030 |
Why?
|
Autoimmune Diseases | 1 | 1999 | 248 | 0.030 |
Why?
|
Italy | 1 | 2016 | 107 | 0.030 |
Why?
|
Signal-To-Noise Ratio | 1 | 2017 | 103 | 0.030 |
Why?
|
tRNA Methyltransferases | 1 | 2016 | 14 | 0.030 |
Why?
|
Mutagenesis, Insertional | 1 | 1997 | 111 | 0.030 |
Why?
|
Decision Making | 2 | 2016 | 655 | 0.030 |
Why?
|
Sexism | 1 | 2016 | 52 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 1996 | 24 | 0.030 |
Why?
|
Genetic Diseases, Inborn | 1 | 1996 | 101 | 0.030 |
Why?
|
Pregnancy Outcome | 1 | 2017 | 252 | 0.030 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2016 | 73 | 0.030 |
Why?
|
Organizations, Nonprofit | 1 | 2015 | 8 | 0.030 |
Why?
|
Aspirin | 1 | 2017 | 157 | 0.030 |
Why?
|
Affect | 1 | 2018 | 387 | 0.030 |
Why?
|
Income | 1 | 2016 | 76 | 0.030 |
Why?
|
Hematopoietic Stem Cells | 1 | 1998 | 297 | 0.030 |
Why?
|
Cisplatin | 2 | 2008 | 615 | 0.030 |
Why?
|
Mismatch Repair Endonuclease PMS2 | 1 | 2015 | 23 | 0.030 |
Why?
|
Critical Care | 1 | 1999 | 373 | 0.030 |
Why?
|
Cosmids | 1 | 1995 | 22 | 0.030 |
Why?
|
Educational Status | 1 | 2016 | 191 | 0.030 |
Why?
|
Interphase | 1 | 1995 | 35 | 0.030 |
Why?
|
Functional Laterality | 2 | 2006 | 201 | 0.030 |
Why?
|
Neoplasms, Experimental | 2 | 2013 | 269 | 0.030 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 1995 | 29 | 0.030 |
Why?
|
Genes, Retinoblastoma | 1 | 1995 | 22 | 0.030 |
Why?
|
Mental Disorders | 1 | 2019 | 405 | 0.030 |
Why?
|
Reference Standards | 2 | 2010 | 143 | 0.030 |
Why?
|
Nucleotides | 1 | 2015 | 96 | 0.030 |
Why?
|
Information Dissemination | 1 | 2015 | 109 | 0.030 |
Why?
|
Adenosine Triphosphatases | 1 | 2015 | 154 | 0.030 |
Why?
|
Cetuximab | 1 | 2015 | 113 | 0.030 |
Why?
|
Methotrexate | 2 | 1997 | 250 | 0.030 |
Why?
|
Public-Private Sector Partnerships | 1 | 2014 | 5 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 1995 | 258 | 0.030 |
Why?
|
Foundations | 1 | 2014 | 15 | 0.030 |
Why?
|
Pain Management | 1 | 2015 | 133 | 0.030 |
Why?
|
Government Agencies | 1 | 2014 | 11 | 0.030 |
Why?
|
Social Support | 1 | 2016 | 203 | 0.030 |
Why?
|
Monocytes | 1 | 1995 | 217 | 0.030 |
Why?
|
Cell Membrane | 2 | 2007 | 667 | 0.030 |
Why?
|
Survivors | 1 | 2015 | 234 | 0.030 |
Why?
|
Dietary Supplements | 1 | 2014 | 128 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2013 | 63 | 0.030 |
Why?
|
Cognition | 1 | 2018 | 577 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2020 | 2317 | 0.030 |
Why?
|
Ethics, Research | 1 | 2014 | 52 | 0.030 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2013 | 36 | 0.030 |
Why?
|
Endothelium | 1 | 2013 | 58 | 0.030 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 21 | 0.030 |
Why?
|
Telomere | 1 | 1994 | 112 | 0.030 |
Why?
|
Claudins | 1 | 2013 | 33 | 0.030 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 44 | 0.030 |
Why?
|
Protein Stability | 1 | 2013 | 100 | 0.030 |
Why?
|
Biomarkers, Pharmacological | 1 | 2013 | 22 | 0.030 |
Why?
|
Caloric Restriction | 1 | 2013 | 14 | 0.030 |
Why?
|
Suppression, Genetic | 1 | 2013 | 30 | 0.030 |
Why?
|
Ultrasonography, Interventional | 1 | 2013 | 123 | 0.030 |
Why?
|
Incidental Findings | 1 | 2013 | 97 | 0.030 |
Why?
|
Immunoblotting | 1 | 2013 | 272 | 0.030 |
Why?
|
Translating | 1 | 2012 | 18 | 0.030 |
Why?
|
Haiti | 1 | 2012 | 21 | 0.030 |
Why?
|
Urinary Bladder | 1 | 1995 | 246 | 0.030 |
Why?
|
Capillary Permeability | 1 | 2013 | 130 | 0.030 |
Why?
|
Oxidants | 1 | 2013 | 86 | 0.030 |
Why?
|
Respiratory Function Tests | 1 | 2013 | 140 | 0.030 |
Why?
|
Nutritional Status | 1 | 2013 | 84 | 0.030 |
Why?
|
Volunteers | 1 | 2012 | 21 | 0.030 |
Why?
|
Environmental Monitoring | 1 | 2013 | 73 | 0.030 |
Why?
|
Oligodendroglioma | 1 | 1992 | 45 | 0.030 |
Why?
|
Equipment and Supplies | 1 | 2012 | 29 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 1996 | 642 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2013 | 271 | 0.030 |
Why?
|
Risk Management | 1 | 2012 | 42 | 0.030 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2013 | 114 | 0.030 |
Why?
|
Drug Interactions | 1 | 2013 | 248 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 2012 | 271 | 0.030 |
Why?
|
Gadolinium DTPA | 1 | 2013 | 261 | 0.030 |
Why?
|
Astrocytoma | 1 | 1992 | 82 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2013 | 271 | 0.030 |
Why?
|
Rural Population | 1 | 2013 | 141 | 0.030 |
Why?
|
History, 21st Century | 1 | 2013 | 177 | 0.030 |
Why?
|
Xeroderma Pigmentosum | 1 | 2011 | 9 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2013 | 425 | 0.030 |
Why?
|
Endonucleases | 1 | 2011 | 21 | 0.030 |
Why?
|
Carcinoembryonic Antigen | 1 | 2011 | 42 | 0.030 |
Why?
|
Sex Factors | 1 | 2015 | 1059 | 0.030 |
Why?
|
Fats | 1 | 2011 | 12 | 0.030 |
Why?
|
Sirolimus | 1 | 2013 | 172 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2013 | 159 | 0.030 |
Why?
|
Anthracyclines | 1 | 2011 | 38 | 0.030 |
Why?
|
Positive Regulatory Domain I-Binding Factor 1 | 1 | 2011 | 13 | 0.030 |
Why?
|
High-Temperature Requirement A Serine Peptidase 1 | 1 | 2011 | 1 | 0.030 |
Why?
|
Air Pollutants | 1 | 2013 | 84 | 0.030 |
Why?
|
Receptors, Steroid | 1 | 2011 | 42 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2013 | 281 | 0.030 |
Why?
|
Antioxidants | 1 | 2013 | 225 | 0.020 |
Why?
|
Rural Health | 1 | 2011 | 21 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2012 | 266 | 0.020 |
Why?
|
Matched-Pair Analysis | 2 | 2002 | 41 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 155 | 0.020 |
Why?
|
HapMap Project | 1 | 2011 | 47 | 0.020 |
Why?
|
Receptors, Growth Factor | 1 | 2011 | 52 | 0.020 |
Why?
|
Mesothelioma | 1 | 1994 | 317 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2011 | 188 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2013 | 632 | 0.020 |
Why?
|
Proteins | 1 | 1996 | 785 | 0.020 |
Why?
|
STAT3 Transcription Factor | 1 | 2011 | 81 | 0.020 |
Why?
|
Sodium-Bicarbonate Symporters | 1 | 2010 | 7 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2012 | 334 | 0.020 |
Why?
|
Gene Silencing | 1 | 2011 | 175 | 0.020 |
Why?
|
Ascites | 1 | 1991 | 57 | 0.020 |
Why?
|
Hepatocyte Growth Factor | 1 | 2011 | 85 | 0.020 |
Why?
|
Species Specificity | 2 | 2007 | 683 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2011 | 157 | 0.020 |
Why?
|
Palliative Care | 1 | 2013 | 263 | 0.020 |
Why?
|
Stem Cells | 1 | 2013 | 364 | 0.020 |
Why?
|
Perception | 1 | 2012 | 176 | 0.020 |
Why?
|
Oils | 1 | 2010 | 6 | 0.020 |
Why?
|
Vesicular Transport Proteins | 1 | 2010 | 63 | 0.020 |
Why?
|
Analysis of Variance | 1 | 1992 | 901 | 0.020 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 1990 | 44 | 0.020 |
Why?
|
Injections | 1 | 2010 | 114 | 0.020 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 1990 | 49 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2013 | 305 | 0.020 |
Why?
|
Patient Care Team | 1 | 2012 | 282 | 0.020 |
Why?
|
Thigh | 1 | 1990 | 39 | 0.020 |
Why?
|
Phosphorylation | 1 | 2012 | 1121 | 0.020 |
Why?
|
Glucose | 1 | 2013 | 628 | 0.020 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2010 | 41 | 0.020 |
Why?
|
Bleomycin | 1 | 1990 | 100 | 0.020 |
Why?
|
MRE11 Homologue Protein | 1 | 2009 | 2 | 0.020 |
Why?
|
Endodeoxyribonucleases | 1 | 2009 | 11 | 0.020 |
Why?
|
Leucovorin | 1 | 1990 | 221 | 0.020 |
Why?
|
Fanconi Anemia Complementation Group Proteins | 1 | 2009 | 8 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2011 | 199 | 0.020 |
Why?
|
Arthralgia | 1 | 2009 | 37 | 0.020 |
Why?
|
Piperazines | 1 | 2011 | 278 | 0.020 |
Why?
|
Indoles | 1 | 2011 | 307 | 0.020 |
Why?
|
Radiography | 1 | 2011 | 810 | 0.020 |
Why?
|
Angiopoietins | 1 | 2009 | 6 | 0.020 |
Why?
|
Translocation, Genetic | 1 | 1990 | 266 | 0.020 |
Why?
|
Cytarabine | 1 | 1990 | 219 | 0.020 |
Why?
|
Cause of Death | 1 | 2010 | 270 | 0.020 |
Why?
|
RNA Helicases | 1 | 2009 | 35 | 0.020 |
Why?
|
Family Practice | 1 | 2009 | 85 | 0.020 |
Why?
|
Organ Specificity | 1 | 2010 | 267 | 0.020 |
Why?
|
Soft Tissue Neoplasms | 1 | 1990 | 129 | 0.020 |
Why?
|
Monocarboxylic Acid Transporters | 1 | 2009 | 80 | 0.020 |
Why?
|
Thiones | 2 | 2000 | 10 | 0.020 |
Why?
|
Symporters | 1 | 2009 | 105 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 2 | 2001 | 173 | 0.020 |
Why?
|
Erlotinib Hydrochloride | 1 | 2008 | 90 | 0.020 |
Why?
|
Carcinoma, Medullary | 1 | 2008 | 11 | 0.020 |
Why?
|
Thiophenes | 2 | 2000 | 43 | 0.020 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2008 | 42 | 0.020 |
Why?
|
Ribosomal Proteins | 1 | 2008 | 45 | 0.020 |
Why?
|
Hawaii | 1 | 2007 | 25 | 0.020 |
Why?
|
Isoleucine | 1 | 2007 | 17 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2009 | 162 | 0.020 |
Why?
|
Etoposide | 1 | 2008 | 197 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 476 | 0.020 |
Why?
|
Threonine | 1 | 2007 | 34 | 0.020 |
Why?
|
Leucine | 1 | 2007 | 67 | 0.020 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2008 | 100 | 0.020 |
Why?
|
Histidine | 1 | 2007 | 55 | 0.020 |
Why?
|
Kinetics | 1 | 2010 | 1528 | 0.020 |
Why?
|
Proline | 1 | 2007 | 57 | 0.020 |
Why?
|
Neurosecretory Systems | 1 | 2007 | 36 | 0.020 |
Why?
|
Aurora Kinases | 1 | 2007 | 17 | 0.020 |
Why?
|
Tyrosine | 1 | 2007 | 133 | 0.020 |
Why?
|
Aurora Kinase A | 1 | 2007 | 11 | 0.020 |
Why?
|
Health Status | 1 | 2009 | 366 | 0.020 |
Why?
|
Fractals | 1 | 2007 | 42 | 0.020 |
Why?
|
Carcinoma, Ductal | 1 | 2007 | 18 | 0.020 |
Why?
|
Cyclin A1 | 1 | 2006 | 2 | 0.020 |
Why?
|
Cathepsin K | 1 | 2006 | 3 | 0.020 |
Why?
|
MSX1 Transcription Factor | 1 | 2006 | 3 | 0.020 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2006 | 12 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2011 | 506 | 0.020 |
Why?
|
Cyclin A | 1 | 2006 | 28 | 0.020 |
Why?
|
Cathepsins | 1 | 2006 | 21 | 0.020 |
Why?
|
DNA Modification Methylases | 1 | 2006 | 28 | 0.020 |
Why?
|
X-Rays | 1 | 2007 | 132 | 0.020 |
Why?
|
Hospitals, Public | 1 | 2006 | 15 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2013 | 1397 | 0.020 |
Why?
|
Remission Induction | 1 | 2008 | 734 | 0.020 |
Why?
|
Aging | 1 | 2011 | 702 | 0.020 |
Why?
|
Israel | 1 | 2006 | 56 | 0.020 |
Why?
|
Keratin-5 | 1 | 2006 | 3 | 0.020 |
Why?
|
Keratin-6 | 1 | 2006 | 3 | 0.020 |
Why?
|
Chronic Disease | 1 | 2009 | 942 | 0.020 |
Why?
|
Keratins | 1 | 2006 | 63 | 0.020 |
Why?
|
Neprilysin | 1 | 2006 | 41 | 0.020 |
Why?
|
Infant | 2 | 2007 | 3105 | 0.020 |
Why?
|
Thionucleosides | 2 | 1997 | 8 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2007 | 193 | 0.020 |
Why?
|
Deoxyadenosines | 2 | 1997 | 23 | 0.020 |
Why?
|
Sample Size | 1 | 2006 | 129 | 0.020 |
Why?
|
Health Policy | 1 | 2007 | 184 | 0.020 |
Why?
|
Menstruation | 1 | 2005 | 34 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2007 | 427 | 0.020 |
Why?
|
Genome | 1 | 2008 | 375 | 0.020 |
Why?
|
CCCTC-Binding Factor | 1 | 2004 | 18 | 0.020 |
Why?
|
NFATC Transcription Factors | 1 | 2004 | 49 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2007 | 431 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2006 | 258 | 0.020 |
Why?
|
Repetitive Sequences, Nucleic Acid | 2 | 1995 | 135 | 0.020 |
Why?
|
Body Water | 1 | 2004 | 35 | 0.020 |
Why?
|
Chromosomes | 1 | 2004 | 97 | 0.020 |
Why?
|
Muscle, Smooth | 1 | 2006 | 354 | 0.020 |
Why?
|
Transcription Factor AP-2 | 1 | 2004 | 14 | 0.020 |
Why?
|
Actins | 1 | 2006 | 454 | 0.010 |
Why?
|
Cell Division | 1 | 2004 | 695 | 0.010 |
Why?
|
Physical Chromosome Mapping | 1 | 2001 | 27 | 0.010 |
Why?
|
5' Untranslated Regions | 1 | 2001 | 51 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2001 | 259 | 0.010 |
Why?
|
Open Reading Frames | 1 | 2001 | 118 | 0.010 |
Why?
|
Scotland | 1 | 2000 | 5 | 0.010 |
Why?
|
Rectum | 1 | 2000 | 148 | 0.010 |
Why?
|
Radiation Injuries | 1 | 2000 | 160 | 0.010 |
Why?
|
beta 2-Glycoprotein I | 1 | 1999 | 5 | 0.010 |
Why?
|
Gangrene | 1 | 1999 | 7 | 0.010 |
Why?
|
Scleroderma, Localized | 1 | 1999 | 9 | 0.010 |
Why?
|
Hematoma, Subdural | 1 | 1999 | 25 | 0.010 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 1999 | 78 | 0.010 |
Why?
|
Leg | 1 | 1999 | 140 | 0.010 |
Why?
|
Cattle | 1 | 1999 | 376 | 0.010 |
Why?
|
Fingers | 1 | 1999 | 68 | 0.010 |
Why?
|
Medical History Taking | 1 | 1998 | 80 | 0.010 |
Why?
|
Azaserine | 1 | 1997 | 4 | 0.010 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 1998 | 42 | 0.010 |
Why?
|
Guanine | 1 | 1999 | 208 | 0.010 |
Why?
|
Antimalarials | 1 | 1997 | 20 | 0.010 |
Why?
|
Societies | 1 | 1997 | 13 | 0.010 |
Why?
|
Reproductive Techniques, Assisted | 1 | 1997 | 15 | 0.010 |
Why?
|
Methionine | 1 | 1997 | 66 | 0.010 |
Why?
|
Cell Count | 1 | 1997 | 197 | 0.010 |
Why?
|
Genetics | 1 | 1997 | 24 | 0.010 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 1996 | 7 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1996 | 28 | 0.010 |
Why?
|
Professional Competence | 1 | 1997 | 69 | 0.010 |
Why?
|
Ischemia | 1 | 1999 | 251 | 0.010 |
Why?
|
Leukemia, T-Cell | 1 | 1995 | 17 | 0.010 |
Why?
|
Leukemia, B-Cell | 1 | 1995 | 23 | 0.010 |
Why?
|
Thrombosis | 1 | 1999 | 301 | 0.010 |
Why?
|
Enzyme Induction | 1 | 1995 | 88 | 0.010 |
Why?
|
Metaphase | 1 | 1995 | 25 | 0.010 |
Why?
|
Ploidies | 1 | 1995 | 41 | 0.010 |
Why?
|
Biological Availability | 1 | 1995 | 92 | 0.010 |
Why?
|
Anticoagulants | 1 | 1999 | 420 | 0.010 |
Why?
|
Genes, Overlapping | 1 | 1994 | 4 | 0.010 |
Why?
|
Area Under Curve | 1 | 1995 | 333 | 0.010 |
Why?
|
Hybrid Cells | 1 | 1994 | 71 | 0.010 |
Why?
|
Adenosine | 1 | 1997 | 237 | 0.010 |
Why?
|
Crossing Over, Genetic | 1 | 1994 | 33 | 0.010 |
Why?
|
Cellular Senescence | 1 | 1995 | 97 | 0.010 |
Why?
|
Gene Library | 1 | 1994 | 132 | 0.010 |
Why?
|
Administration, Oral | 1 | 1995 | 680 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 1999 | 990 | 0.010 |
Why?
|
Tetrahydrofolates | 1 | 1993 | 13 | 0.010 |
Why?
|
Interferon-beta | 1 | 1994 | 125 | 0.010 |
Why?
|
Carcinoma, Transitional Cell | 1 | 1995 | 168 | 0.010 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 1992 | 47 | 0.010 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1992 | 147 | 0.010 |
Why?
|
Rats | 1 | 1997 | 4022 | 0.010 |
Why?
|
Blast Crisis | 1 | 1990 | 36 | 0.010 |
Why?
|
Burkitt Lymphoma | 1 | 1990 | 32 | 0.010 |
Why?
|
Genes, Immunoglobulin | 1 | 1990 | 111 | 0.010 |
Why?
|
Immunophenotyping | 1 | 1990 | 215 | 0.010 |
Why?
|
Lymphoma, Follicular | 1 | 1990 | 73 | 0.010 |
Why?
|
Biological Evolution | 1 | 1994 | 937 | 0.000 |
Why?
|